Home
Jarl Underhaug's picture

Jarl Underhaug

Associate Professor, Manager of the Norwegian NMR Platform

Structural biology

Academic article
  • Show author(s) 2021. Emulsion and Surface-Active Properties of Fish Solubles Based on Direct Extraction and after Hydrolysis of Atlantic Cod and Atlantic Salmon Backbones. Foods. 1-13.
  • Show author(s) 2020. The Arabidopsis (ASHH2) CW domain binds monomethylated K4 of the histone H3 tail through conformational selection. The FEBS Journal. 4458-4480.
  • Show author(s) 2020. Sensory Assessment of Fish and Chicken Protein Hydrolysates. Evaluation of NMR Metabolomics Profiling as a New Prediction Tool. Journal of Agricultural and Food Chemistry. 3881-3890.
  • Show author(s) 2019. Quantification of polyphenols in seaweeds: A case study of Ulva intestinalis. Antioxidants. 1-15.
  • Show author(s) 2019. Anionic hafnium species: an active catalytic intermediate for the coupling of epoxides with CO2? . Chemical Communications. 7227- 7230.
  • Show author(s) 2019. A Pharmacological Chaperone Therapy for Acute Intermittent Porphyria. Molecular Therapy.
  • Show author(s) 2017. Pharmacological Chaperoning: A Potential Treatment for PMM2-CDG. Human Mutation. 160-168.
  • Show author(s) 2017. New perspectives for pharmacological chaperoning treatment in methylmalonic aciduria cblB type. Biochimica et Biophysica Acta - Molecular Basis of Disease. 640-648.
  • Show author(s) 2017. Conformational stabilization as a strategy to prevent nucleophosmin mislocalization in leukemia. Scientific Reports.
  • Show author(s) 2015. Linking genotypes database with locus-specific database and genotype-phenotype correlation in phenylketonuria. European Journal of Human Genetics. 302-309.
  • Show author(s) 2015. Early Events in the Amyloid Formation of the A546T Mutant of Transforming Growth Factor β‑Induced Protein in Corneal Dystrophies Compared to the Nonfibrillating R555W and R555Q Mutants. Biochemistry. 5546-5556.
  • Show author(s) 2015. Discovery of compounds that protect tyrosine hydroxylase activity through different mechanisms. Biochimica et Biophysica Acta - Proteins and Proteomics. 1078-1089.
  • Show author(s) 2015. Discovery of a Specific Inhibitor of Pyomelanin Synthesis in Legionella pneumophila. Journal of Medicinal Chemistry. 8402-8412.
  • Show author(s) 2013. Screening and evaluation of small organic molecules as ClpB inhibitors and potential antimicrobials. Journal of Medicinal Chemistry. 7177-7189.
  • Show author(s) 2013. Pharmacological chaperones as a potential therapeutic option in methylmalonic aciduria cblB type. Human Molecular Genetics. 3680-3689.
  • Show author(s) 2013. Mutation in transforming growth factor beta induced protein associated with granular corneal dystrophy type 1 reduces the proteolytic susceptibility through local structural stabilization. Biochimica et Biophysica Acta - Proteins and Proteomics. 2812-2822.
  • Show author(s) 2012. The peripheral binding of 14-3-3gamma to membranes involves isoform-specific histidine residues. PLOS ONE.
  • Show author(s) 2012. In situ solid-state NMR spectroscopy of protein in heterogeneous membranes: the baseplate antenna complex of chlorobaculum tepidum. Angewandte Chemie International Edition. 6891-6895.
  • Show author(s) 2012. A vitellogenin polyserine cleavage site: highly disordered conformation protected from proteolysis by phosphorylation. Journal of Experimental Biology. 1837-1846.
  • Show author(s) 2011. The binding of 14-3-3 gamma to membranes studied by intrinsic fluorescence spectroscopy. FEBS Letters. 1163-1168.
  • Show author(s) 2008. Large-scale modulation of thermodynamic protein folding barriers linked to electrostatics. Proceedings of the National Academy of Sciences of the United States of America. 8625-8630.
  • Show author(s) 2005. Conformational flexibility of alpha-lactalbumin related to its membrane binding capacity. Journal of Molecular Biology (JMB). 1072-1086.
Academic lecture
  • Show author(s) 2015. Experimental structures of human 8-oxoguanine glycosylase 1 in complex with novel inhibitors.
Abstract
  • Show author(s) 2010. POTENTIAL PHARMACOLOGYCAL CHAPERONE THERAPY FOR ISOLATED METHYLMALONIC ACIDURIA cbIB TYPE. The Journal of Inherited Metabolic Disease (JIMD). S40-S40.
  • Show author(s) 2010. Characterization of the molecular basis of acute intermittent porphyria. The FEBS Journal. 76-76.
  • Show author(s) 2010. CHARACTERIZATION OF THE MOLECULAR BASIS OF ACUTE INTERMITTENT PORPHYRIA. The Journal of Inherited Metabolic Disease (JIMD). S177-S177.
Errata
  • Show author(s) 2016. Erratum: Discovery of compounds that protect tyrosine hydroxylase activity through different mechanisms (Biochimica et Biophysica Acta - Proteins and Proteomics (2015) 1854:9 (1078-1089) DOI: 10.1016/j.bbapap.2015.04.030). Biochimica et Biophysica Acta - Proteins and Proteomics. 317.
Academic literature review
  • Show author(s) 2016. Pharmacological chaperones that protect Tetrahydrobiopterin dependent aromatic amino acid hydroxylases through different mechanisms. Current Drug Targets. 1515-1526.
  • Show author(s) 2012. Phenylalanine hydroxylase misfolding and pharmacological chaperones. Current Topics in Medicinal Chemistry. 2534-2545.
Chapter
  • Show author(s) 2020. Differential scanning fluorimetry in the screening and validation of pharmacological chaperones for soluble and membrane proteins. 329-343. In:
    • Show author(s) 2020. Protein Homeostasis Diseases: Mechanisms and Novel Therapies. Elsevier.

More information in national current research information system (CRIStin)

Research groups